Epirubicin Hydrochloride for Injection.

Effects and efficacy: This product can be used to treat malignant lymphoma, breast cancer, lung cancer, soft tissue sarcoma, esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, melanoma, colorectal cancer, ovarian cancer, multiple myeloma, and leukemia. Intravesical administration is helpful for the treatment of superficial bladder cancer and carcinoma in situ and the prevention of recurrence after transurethral resection.
Usage and dosage:
1. Conventional dose for intravenous infusion: When epirubicin is used alone, the adult dose is 60-120 mg/m2 per body surface area once; when epirubicin is used as an adjuvant treatment for breast cancer patients with positive axillary lymph nodes combined with chemotherapy, the recommended starting dose is 100-120 mg/m2 intravenous injection. The total starting dose for each course of treatment can be administered once or in divided doses for 2-3 consecutive days. It can be repeated at intervals of 21 days depending on the patient’s blood picture. Optimized dose: High doses can be used to treat lung cancer and breast cancer. When used alone, the recommended starting dose for adults is up to 135 mg/m2 per body surface area, administered once on the first day of each course of treatment or divided into doses on the first, second, and third days of each course of treatment, once every 3-4 weeks. When used in combination with chemotherapy, the recommended starting dose is up to 120 mg/m2 per body surface area, administered on the first day of each course of treatment, once every 3-4 weeks. Administered by intravenous injection. Can be repeated at intervals of 21 days depending on the patient’s blood count. 2. Intravesical administration: Epirubicin should be instilled through a catheter and should remain in the bladder for about an hour. During instillation, the patient should change position frequently to ensure that the bladder mucosa can be exposed to the drug over the largest area. To avoid inappropriate dilution of the drug by urine, the patient should be informed not to drink any liquids 12 hours before instillation. The doctor should instruct the patient to empty the urine at the end of treatment. For superficial bladder cancer, epirubicin 50 mg is dissolved in 25 to 50 mL of normal saline and instilled once a week for 8 times. For cases with local toxicity (chemical cystitis), the dose can be reduced to 30 mg per time. Patients can also receive 50 mg once a week for 4 times, then once a month for 11 times. The doctor can adjust the number of doses according to the patient’s condition. The same drug produced by different manufacturers may have inconsistent instructions. If you find that the instructions are inconsistent before taking the drug, please consult a doctor or pharmacist in time.
Drug contraindications:
Contraindicated during lactation, contraindicated for allergies to this product, contraindicated for liver and kidney dysfunction, use with caution, use with caution during pregnancy, use with caution for infants under 6 months old
Related dosage forms:
Injection